三阴性乳腺癌患者RGS20 mRNA表达水平及与临床预后的关系分析

目的探究RGS20 mRNA在三阴性乳腺癌患者中的表达水平,并分析与临床预后的关系。方法随机收集2013年6月-2015年6月入院治疗三阴性乳腺癌的患者82例,采用qRT-PCR检测患者乳腺癌组织和癌旁正常组织中RGS20 m RNA的表达,采用免疫组化检测三阴性乳腺癌患者乳腺癌组织中RGS20的表达,并分析其表达与三阴性乳腺癌临床特征的关系及预后的影响。结果三阴性乳腺癌组织中RGS20 mRNA的表达显著高于癌旁组织(t=13.006,P=0.000);三阴性乳腺癌组织中RGS20阳性表达率为68.29%,显著高于癌旁组织15.85%(χ^2=46.260,P=0.000);三阴性乳腺癌患者不同淋巴结的转移情况、临床分期及Ki67百分比等临床病理特征中RGS20的表达具有显著性差异(χ^2=4.666、5.781、4.167,P=0.031、0.016、0.041);随访36个月,RGS20阳性表达的三阴性乳腺癌患者3年无疾病生存期(DFS)和3年总生存期(OS)均显著低于阴性表达的患者(Log-rankχ^2=3.904、4.957,P=0.048、0.026)。结论 RGS20在三阴性乳腺癌组织中过表达,其表达在不同淋巴结转移情况、临床分期及Ki67中表达百分比有显著差异,且RGS20阴性表达的三阴性乳腺癌患者生存时间明显较高,可作为三阴性乳腺癌潜在的治疗靶点和预后预测因子。

Analysis of expression level of RGS20 mRNA and its relationship with clinical prognosis in patients with triple-negative breast cancer

Objective To explore the expression level of RGS20 mRNA in patients with triple-negative breast cancer and to analyze its relationship with clinical prognosis.Methods A total of 82 patients with triple-negative breast cancer admitted to hospital from June 2013 to June 2015 were randomly collected.The expression level of RGS20 m RNA in breast cancer tissues and adjacent normal tissues was detected by qRT-PCR.The expression level of RGS20 in breast cancer tissues of patients with triplenegative breast cancer was detected by immunohistochemistry,and the relationship between its expression and clinical features of patients with triple-negative breast cancer and the effects on prognosis were analyzed.Results The expression level of RGS20 mRNA in triple-negative breast cancer tissues was significantly higher than that in adjacent tissues(t=13.006,P=0.000).The positive expression rate of RGS20 in triple-negative breast cancer tissues was significantly higher than that in adjacent tissues(68.29%vs 15.85%)(χ^2=46.260,P=0.000).There was a significant difference in the expression of RGS20 of triple-negative breast cancer patients with clinicopathological features of different lymph node metastasis,clinical stage and Ki67 percentage(χ^2=4.666,5.78,4.167,P=0.031,0.016,0.041).At 36-month follow-up,the 3-year disease-free survival(DFS) and 3-year overall survival(OS) of triple-negative breast cancer patients with positive RGS20 expression were significantly lower than those of patients with negative expression(Log-rank χ^2=3.904,4.957,P=0.048,0.026).Conclusion RGS20 is overexpressed in triple-negative breast cancer tissues,and its expression is significantly different in triple-negative breast cancer patients with different lymph node metastasis,clinical stage and Ki67 percentage,and negative expression of RGS20 can improve the survival rate of patients with triple-negative breast cancer,and it can be used as a potential therapeutic target and prognostic predictor of triple-negative breast cancer.